Any forward-looking student of the biotech industry will have to check out Adam Feuerstein's review in TheStreet of 22 Phase II and III clinical trials--21 drugs and one diagnostic test--which are expected to read out by the end of this year.
One of the savviest analysts in the business, Feuerstein runs through snaps on studies for Arqule (the closely watched tivantinib cancer study), Biogen Idec (trying to diversify into hemophilia and ALS), Celgene (apremilast for RA and psoriasis) and, of course, the big Alzheimer's studies for solanezumab and bapineuzumab, among others.
As Feuerstein notes in his report, big studies have a way of either rehabilitating developers' share prices or driving them into the ground. Over the second half of this year we're likely to see plenty of examples of both scenarios as the data hits.
- here's the story from TheStreet